期刊文献+

重庆市耐多药肺结核可疑患者药敏结果分析 被引量:7

Drug susceptibility test to anti-tuberculosis drugs from the suspected MDR-TB patients in Chongqing
下载PDF
导出
摘要 目的:通过分析重庆市耐多药肺结核(multidrug-resistant tuberculosis,MDR-TB)可疑患者药敏结果,为重庆市耐多药结核病的发现及控制提供参考和依据。方法:2014年7月至2016年2月重庆市39个区县573例MDR-TB可疑患者痰培养阳性分离株,采用比例法进行4种一线抗结核药物和6种二线抗结核药物的药敏试验,对药敏结果进行统计分析。结果:573例MDR-TB可疑患者的MDR-TB检出率为25.0%,明显高于单耐药结核病(single drug-resistant tuberculosis,SDR-TB)检出率(9.6%)及多耐药结核病(poly drug-resistant tuberculosis,PDR-TB)检出率(8.0%)(P<0.001)。高危人群MDR-TB检出率为26.6%(130/488),明显高于新患者的15.3%(13/85)(P=0.026)。高危人群中,复治失败患者MDR-TB检出率最高,为42.1%(16/38),其次为初治失败患者,为40.0%(18/45)。结论:重庆市耐多药肺结核可疑患者MDR-TB检出率高,耐多药肺结核防控形势严峻。高危人群尤其是复治失败和初治失败患者应该作为耐多药肺结核筛查的重点人群。 Objective:To analyze the drug susceptibility of M.tuberculosis isolates from suspected multidrug-resistant tuberculosis (MDR-TB) patients in Chongqing, so as to provide scientific evidence for MDR-TB discovery and control. Methods:Totally 573 M.tuberculosis isolates from suspected MDR-TB patients were collected from July 2014 to February 2016. Four kinds of first-line anti-TB drugs (INH, RFP, Sm, EMB) and six kinds of second-line drugs (Ofx, Km, Cm, Pto, PAS, Am) were tested for susceptibility by the proportion method. Results:Among the 573 suspected MDR-TB cases, 143 cases(25.0%) were identified as MDR-TB, meanwhile, 55 cases (9.6%) were single drug-resistant tuberculosis (SDR-TB) and 46 cases (8.0%) were poly drug-resistant tuberculosis (PDR-TB). The proportion of MDR-TB was significantly higher than that of SDR-TB and PDR-TB(P〈0.001 ). In terms of MDR- TB,the high risk groups had a higher drug resistance rate(26.6%, 130/488) than the new patients(15.3%, 13/85),P=0.026. Among the high risk groups,the detection rate of MDR-TB was the highest(42.1%, 16/38) in the patients who failed in the re-treatment,followed by those failed in the initial treatment(40.0%, 18/45). Conclusion:The detection rate of MDR-TB is moderately high among the suspected MDR-TB patients in Chongqing. A long way remained to go in controlling MDR-TB. The screening for MDR-TB should target at high risk groups especially the patients failed in the re-treatment and initial treatment.
作者 胡彦 杨春 卢楠 刘洁 刘英 余锋平 沈静 朱大冕 冯鑫 王晓英 Hu Yan;Yang Chun;Lu Nan;Liu Jie;Liu Yin;Yu Fengping;Shen Jing;Zhu Damian;Feng Xin;Wang Xiaoying(Tuberculosis Reference Laboratory, Chongqing Institute for Tuberculosis Control and Prevention;Teaching and Research Section of Pathogen Biology, College of Basic Medicine, Chongqing Medical University)
出处 《重庆医科大学学报》 CAS CSCD 北大核心 2018年第7期923-926,共4页 Journal of Chongqing Medical University
关键词 结核分枝杆菌 耐多药 高危人群 药敏试验 重庆市 Mycobacterium tuberculosis multidrug-resistance high risk groups durg susceptibility testing Chongqing
  • 相关文献

参考文献4

二级参考文献30

  • 1高微微,赵雁林,刘宇红,王敬,黄学锐,谢莉.104例不同程度耐多药肺结核的临床分析[J].中国防痨杂志,2008,30(2):114-117. 被引量:15
  • 2肖东楼.中国结核病防治工作进展与成就[J].中国防痨杂志,2008,30(6):491-493. 被引量:34
  • 3T.Heller,R.J.Lessells,C.G.Wallrauch,T.Brnighausen,G.S.Cooke,L.Mhlongo,I.Master,M.L.Newell,弭凤玲,王雪静.南非夸祖鲁纳塔尔农村地区以社区为基础的耐多药结核病治疗[J].国际结核病与肺部疾病杂志,2010(3):110-115. 被引量:17
  • 4李建翠.涂阳培阴结核菌检查结果的观察[J].实用全科医学,2006,4(1):71-71. 被引量:4
  • 5中华人民共和国卫生部.全国结核病耐药性基线调查报告(2007—2008年)[R].北京:人民卫生出版社.2010.
  • 6中华人民共和围卫生部.全国结核病耐药性基线调硷报告(2007-2008年)[M].北京:人民卫生出版社,2010:3.
  • 7World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: World Health Organization, 2008.
  • 8Blower SM, Chou T. Modeling the emergence of the hot zones' :tuberculosis and the amplification dynamics of drug re sistance. Nat Med, 2004,10(10) : 1111-1116.
  • 9World Health Organization. Guidelines for establishing DOTS- Plus pilot projects for the management of multidrug-resistant tuberculosis(MDR TB). Geneva:World Health Organization,2000.
  • 10全国结核病耐药性基线调查办公室.全国结核病耐药性基线调查实施手册.北京:中国协和医科大学出版社,2007.

共引文献70

同被引文献56

引证文献7

二级引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部